Clinical Trial Update: Evaluation of Long-term Safety, and Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects With Epilepsy [Phase 3]

View source ↗

Summary

Phase 3 long-term safety and efficacy results for brivaracetam as adjunctive therapy in epilepsy were reported, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy

Drugs mentioned

• BRIVARACETAM (brivaracetam)

Snippet

Sponsor: UCB Pharma SA | Conditions: Epilepsy | Phase 3 | Status: COMPLETED | Results posted: 2017-08-02